Advanced Head and Neck Squamous Cell Carcinoma
Oncology·MeSH: Carcinoma, Hepatocellular
Prevalence
14.0 / 100K
Incidence
6.0 / 100K/yr
3 drugs in development·3 companies·3 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Volrustomig | ASTRAZENECA PLC (AZN) |
Phase 2(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Advanced Head and Neck Squamous Cell Carcinoma?
BioSniper tracks 3 drugs in development for Advanced Head and Neck Squamous Cell Carcinoma across 3 companies.
How many clinical trials target Advanced Head and Neck Squamous Cell Carcinoma?
There are 3 clinical trials targeting Advanced Head and Neck Squamous Cell Carcinoma tracked by BioSniper.
What is the prevalence of Advanced Head and Neck Squamous Cell Carcinoma?
The estimated prevalence of Advanced Head and Neck Squamous Cell Carcinoma is approximately 14.0 per 100,000 population.
Deep-dive into Advanced Head and Neck Squamous Cell Carcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis